Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 203

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 203
---
 while the marketing rights for the rest of the world are held by Teli. We have performed Teli’s valuation (and Telomir’s valuation) under the assumption that the developing costs will be expensed equally by both companies, even if the actual development is performed by only one of them.

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 15 of 24 |

Timeline of the development of the Indications

Based on information received from the company and our own research we have assumed the following regarding the development of the AMD and Breast cancer Indications:

The timeline is presented in the following chart:

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 16 of 24 |

Total Available Markets

The company holds the exclusive license rights for all the world other than North America. Our estimations of the potential markets are based on the European markets.

AMD

Our estimations of the AMD market size are based on the prevalence of Dry AMD (Early and Late stages) in the European population 4.

The valuation is based on estimations of the future populations in these markets, as follows (New Treatable cases):

4 https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/#tbl1

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 17 of 24 |

Breast Cancer

The estimations of the Breast Cancer population are based on the Incidence rates of Breast Cancer in the Female population of Europe in 2022, as follows 5, 6, 7:

We assumed that the new developed drug would treat only cancer stages I – III. Data regarding the number of treatable cases (stages I – III) are based on estimations of 2025 Female populations in each of the geographical areas mentioned.

The above figures are based on the current adult populations in each of the geographical markets. The valuation is based on estimations of the future populations in these markets, as follows (New Treatable cases):

Market Share

Our assumptions regarding the market shares of each indication in all the markets are as follows:

5 https://www.wcrf.org/preventing-cancer/cancer-statistics/breast-cancer-statistics/?utm_source=chatgpt.com#breast-cancer-incidence-cases

6https://gco.iarc.who.int/media/globocan/factsheets/populations/276-germany-fact-sheet.pdf

7 https://gco.i